Clinical Trial Update: Efficacy and Safety of Ixekizumab in Patients with Refractory Guttate Psoriasis [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on ixekizumab for guttate psoriasis across Phase 2 and Phase 3; status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Guttate Psoriasis

Drugs mentioned

• TALTZ (IXEKIZUMAB)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Guttate Psoriasis | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING